200
Participants
Start Date
January 7, 2021
Primary Completion Date
June 30, 2026
Study Completion Date
December 31, 2026
Acetazolamide + supplemental oxygen + PAP therapy
Every participant will undergo measurement of the apneic threshold. The apneic threshold (AT) can be determined by inducing central apnea using non-invasive ventilation (NIV) or eliminating central apnea using supplemental CO2. The requisite change to induce central apnea is referred to as the CO2 reserve, which can be positive or negative. The central apnea index and the apneic threshold will be measured while participants receiving medication or oxygen (or both). In addition, participants will get PAP therapy during all the conditions.
Zolpidem + PAP therapy
The central apnea index and the apneic threshold will be compared under two conditions: zolpidem or placebo. In addition, participants will get PAP therapy during both the conditions.
Buspirone + PAP therapy
The central apnea index and the apneic threshold will be compared under two conditions: buspirone or placebo. In addition, participants will get PAP therapy during both the conditions.
RECRUITING
John D. Dingell VA Medical Center, Detroit, MI, Detroit
VA Office of Research and Development
FED